✦ LIBER ✦

825 Statistical analysis of survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (‘Iressa’, ZD1839) in an expanded access program (EAP): preliminary results

✍ Scribed by M. Wolf; D. Farina-Sisofo; J. Grous; G. Kennealey; J. Ochs

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Outcomes of patients with advanced non-s

✍ Jänne, Pasi A.; Gurubhagavatula, Sarada; Yeap, Beow Y.; Lucca, Joan; Ostler, Pat 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 134 KB

P-587 Experience from a large multi-cent

✍ van Puijenbroek, R.; Bosquée, L.; Tits, G.; Germonpre, P.; Strobbe, E.; Vansteen 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 294 KB

Activity of ZD1839 (Gefitinib, Iressa™)

✍ Angelia D. Gibson; Mark Socinski; Chandra P. Belani; Vinay K. Jain 📂 Article 📅 2002 🏛 CIG Media Group, LP. 🌐 English ⚖ 79 KB

O-243 Clinical benefits in patients with

✍ Janne, Pasi A.; Gurubhagavatula, Sarada; Lucca, Joan; Ostler, Patricia; Skarin, 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 193 KB

Efficacy and safety of gefitinib in chem

✍ Govindan, Ramaswamy; Natale, Ronald; Wade, James; Herbst, Roy; Krebs, Annetta; R 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Combination therapy with ZD1839 (‘Iressa

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 137 KB